Cytokinetics to Release Q2 Results on August 8, 2024

SOUTH SAN FRANCISCO, Calif., July 25, 2024 – Cytokinetics, Incorporated (Nasdaq: CYTK) has announced it will release its second-quarter financial results on August 8, 2024, at 4:00 PM Eastern Time. Following the announcement, the company's senior management will hold a conference call at 4:30 PM Eastern Time to discuss the operational and financial outcomes as well as the company's future outlook. The conference call will be webcast live and accessible via the Investors & Media section of Cytokinetics’ website. Additionally, participants can access the call by registering in advance to receive a dial-in number and a unique passcode. An archived replay of the webcast will be available on the company's website for twelve months.

Cytokinetics is a biopharmaceutical company in the late stages of development, focusing on cardiovascular diseases by targeting muscle biology. The company specializes in discovering, developing, and commercializing small molecule drug candidates designed to improve muscle function. One of its leading projects is aficamten, a cardiac myosin inhibitor aimed at treating obstructive hypertrophic cardiomyopathy (HCM). Positive results from the SEQUOIA-HCM Phase 3 clinical trial have prompted the company to prepare for regulatory submissions.

The company is also conducting several other trials involving aficamten. The MAPLE-HCM trial is comparing aficamten as a monotherapy to metoprolol in patients with obstructive HCM. The ACACIA-HCM trial is investigating aficamten's efficacy in patients with non-obstructive HCM. Additionally, the CEDAR-HCM trial is focusing on pediatric patients with obstructive HCM, while the FOREST-HCM study is an open-label extension trial for patients with HCM.

Another key drug in Cytokinetics' pipeline is omecamtiv mecarbil, designed for patients with heart failure as a cardiac muscle activator. The company is also developing CK-586, another cardiac myosin inhibitor but with a different mechanism of action than aficamten, targeting heart failure with preserved ejection fraction (HFpEF). CK-136, a cardiac troponin activator, is being developed for the treatment of heart failure with reduced ejection fraction (HFrEF) and other heart failure conditions like right ventricular failure due to impaired cardiac contractility.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!